SPPI
Price:
$1.025
Market Cap:
$210.38M
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma. It has co-development, commercialization, and in-license...[Read more]
Industry
Biotechnology
IPO Date
1996-09-26
Stock Exchange
NASDAQ
Ticker
SPPI
According to Spectrum Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current ROE is -119.31%. This represents a change of 139.52% compared to the average of -49.81% of the last 4 quarters.
The mean historical ROE of Spectrum Pharmaceuticals, Inc. over the last ten years is -97.32%. The current -119.31% ROE has changed 22.60% with respect to the historical average. Over the past ten years (40 quarters), SPPI's ROE was at its highest in in the June 2018 quarter at 3.99%. The ROE was at its lowest in in the June 2022 quarter at -86.85%.
Average
-97.32%
Median
-35.70%
Minimum
-333.18%
Maximum
-17.96%
Discovering the peaks and valleys of Spectrum Pharmaceuticals, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 161.14%
Maximum Annual ROE = -17.96%
Minimum Annual Increase = -166.48%
Minimum Annual ROE = -333.18%
Year | ROE | Change |
---|---|---|
2022 | -280.06% | -15.94% |
2021 | -333.18% | 161.14% |
2020 | -127.58% | 79.42% |
2019 | -71.11% | 67.84% |
2018 | -42.37% | 63.13% |
2017 | -25.97% | -10.53% |
2016 | -29.03% | 21.66% |
2015 | -23.86% | 32.84% |
2014 | -17.96% | -18.60% |
2013 | -22.06% | -166.48% |
The current ROE of Spectrum Pharmaceuticals, Inc. (SPPI) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-246.94%
5-year avg
-170.86%
10-year avg
-97.32%
Spectrum Pharmaceuticals, Inc.’s ROE is less than Selecta Biosciences, Inc. (67.13%), less than Paratek Pharmaceuticals, Inc. (22.36%), greater than Corvus Pharmaceuticals, Inc. (-53.99%), greater than Immutep Limited (-42.11%), greater than Icosavax, Inc. (-41.24%), greater than Ardelyx, Inc. (-39.73%), greater than Zura Bio Limited (-35.45%), greater than Hepion Pharmaceuticals, Inc. (-328.66%), less than AVROBIO, Inc. (29.68%), greater than Verastem, Inc. (-133.02%), greater than Agios Pharmaceuticals, Inc. (-47.05%), greater than bluebird bio, Inc. (-38.30%), greater than Intercept Pharmaceuticals, Inc. (-78.24%), less than Karyopharm Therapeutics Inc. (66.89%), less than BioLineRx Ltd. (0%), greater than Lexicon Pharmaceuticals, Inc. (-225.62%), less than Seres Therapeutics, Inc. (73.27%), less than ImmunityBio, Inc. (313.56%), less than Gamida Cell Ltd. (100.06%), less than Rigel Pharmaceuticals, Inc. (187.96%), less than Geron Corporation (46.64%), greater than ImmunoGen, Inc. (-73.79%), greater than null (-21.97%),
Company | ROE | Market cap |
---|---|---|
67.13% | $135.20M | |
22.36% | $127.83M | |
-53.99% | $252.08M | |
-42.11% | $382.21M | |
-41.24% | $769.04M | |
-39.73% | $1.32B | |
-35.45% | $230.86M | |
-328.66% | $4.20M | |
29.68% | $5.24M | |
-133.02% | $96.58M | |
-47.05% | $2.46B | |
-38.30% | $101.94M | |
-78.24% | $794.69M | |
66.89% | $91.04M | |
0% | $55.61M | |
-225.62% | $582.00M | |
73.27% | $145.36M | |
313.56% | $2.35B | |
100.06% | $4.34M | |
187.96% | $234.37M | |
46.64% | $2.56B | |
-73.79% | $8.73B | |
-21.97% | $0 |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Spectrum Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Spectrum Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Spectrum Pharmaceuticals, Inc.'s ROE?
How is the ROE calculated for Spectrum Pharmaceuticals, Inc. (SPPI)?
What is the highest ROE for Spectrum Pharmaceuticals, Inc. (SPPI)?
What is the 3-year average ROE for Spectrum Pharmaceuticals, Inc. (SPPI)?
What is the 5-year average ROE for Spectrum Pharmaceuticals, Inc. (SPPI)?
How does the current ROE for Spectrum Pharmaceuticals, Inc. (SPPI) compare to its historical average?